Quest Diagnostics (DGX) has just posted its Q2 2026 numbers, with revenue of US$3.0 billion, basic EPS of US$2.88 and net income of US$320 million setting the tone for the latest update. The company has seen revenue move from US$2.76 billion and EPS of US$2.51 in Q2 2025 to US$3.0 billion and EPS of US$2.88 in Q2 2026. Trailing 12 month revenue sits at US$11.6 billion with basic EPS of US$9.62. With net margin for the trailing period a touch higher than last year and earnings up over the past 12 months after several years of average declines, this set of results gives investors plenty to weigh around how sustainable current profitability really is.

See our full analysis for Quest Diagnostics.

With the latest quarter in hand, the next step is to see how these numbers line up against the widely followed narratives around Quest Diagnostics. This will highlight where the story is being reinforced and where it might be getting challenged.

TTM earnings of US$1.06b change the context

• On a trailing basis, Quest Diagnostics has US$1.06b in net income and US$9.62 in basic EPS across US$11.56b of revenue, compared with five year average earnings that declined 18.6% per year and last year earnings growth of 12%.
• What stands out for a bullish view built around Quest Diagnostics as a defensive healthcare business is that higher trailing earnings now back up that story. However, the five year earnings decline and only 4.3% forecast annual revenue growth sit in the background as a reminder this is not a high growth profile.
  • Supporters pointing to steadier cash generation can now reference US$1.06b of trailing net income and a 9.2% net margin, which is slightly above last year’s 9.0% margin.
  • At the same time, anyone expecting rapid expansion has to weigh those figures against the long run 18.6% annual decline in earnings, even with the more recent 12% year over year improvement.

To see how community narratives connect these improving earnings to the longer term story for Quest Diagnostics, check out the 📊 Read the what the Community is saying about Quest Diagnostics..

P/E of 23.8x and DCF fair value of US$328.86

• The stock trades on a P/E of 23.8x versus a US Healthcare industry average of 25.5x and a peer average of 40.2x, and the current share price of US$227.86 sits well below a DCF fair value of US$328.86 as well as below an analyst price target of US$239.38.
• For a bullish angle that treats Quest Diagnostics as relatively reasonably priced, valuation metrics heavily support that case, although they do not remove risk.
  • The lower P/E than both industry and peer averages, together with the indicated 30.7% gap to DCF fair value, lines up with arguments that investors are not overpaying for the trailing 9.2% net margin and US$9.62 of EPS.
  • On the other hand, the modest 1.51% dividend yield and slower forecast revenue growth of 4.3% per year give bulls concrete constraints to factor in alongside the apparent valuation support.

Debt load contrasts with 1.51% dividend

• The company is flagged as having a high level of debt while at the same time offering a 1.51% dividend yield on the current share price of US$227.86, all against trailing net income of US$1.06b.
• Critics focused on a more cautious angle will highlight that valuation support does not eliminate balance sheet risk, and the income stream is modest relative to that leverage.
  • The minor risk tag on debt means investors need to weigh repayment capacity, even though earnings over the last year rose 12% after several years where earnings declined on average by 18.6% per year.
  • Income oriented holders may welcome the steady dividend, but at 1.51% they still rely heavily on the company maintaining US$1.06b of earnings and a 9.2% net margin for the stock to remain attractive in their portfolios.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Quest Diagnostics's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

Seeing both risks and rewards in Quest Diagnostics, but unsure how it all stacks up for you personally? Take a closer look at the underlying figures, compare them with your own expectations, and then weigh the 4 key rewards and 1 important warning sign.

See What Else Is Out There

Quest Diagnostics offers solid earnings and valuation support, but its high debt level, modest 1.51% dividend yield and past earnings declines leave income and risk focused investors wanting more.

If you want stronger capital protection and steadier financial footing than Quest Diagnostics currently offers, check out the 81 resilient stocks with low risk scores to quickly spot companies with more resilient profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.